RESUMEN
[ABSTRACT]OBJECTIVETo observe the short term effects and adverse effects of induction chemotherapy with Paclitaxel,Cisplatin and Fluorouracil(TPF) in locally advanced squamous cell cancer of hypopharynx. METHODS78 cases locally advanced squamous-cell cancer of hypopharynx form jan 2011 to oct 2013 for the first time treated by TPF scheme,after 2 cycles,to recheck CT scan and evaluate therapeutic effective.RESULTSAll 78 cases patients achieved 156 cycles chemotherapy,CR was 4 cases (5.1%),PR 55 cases (70.5%),SD 17 cases (21.8%), PD 2 cases (2.6%). Total effective rate (CR+PR) was 75.6%,and with low incidence ofⅢ/Ⅳ grade side effect. Logistic regression analysis shows that there is a significant correlation between effective rate and low differentiation cancer.CONCLUSIONFor locally advanced squamous-cell cancer of hypopharynx patients,the TPF chemotherapy scheme showed good therapeutic effective and safety,could be a choice for the induction chemotherapy treatment in locally advanced squamouscell cancer of hypopharynx. The patients with low differentiation cancer may have benefit from the induction chemotherapy.
RESUMEN
Introducción. La secuencia de Pierre-Robin (SPR) es una afección congénita caracterizada por micrognatia, glosoptosis y fsura del paladar blando. La prevalencia es 1:8500 recién nacidos (RN) vivos. El hepatoblastoma (HB) es el tumor maligno primario de hígado más frecuente en pediatría. Afecta niños menores de 3 años. Caso clínico. Se trata de un paciente masculino de 2 años de edad, producto de la gesta II, de término, obtenido por cesárea, peso al nacer de 2, 750 g, con diagnóstico de SPR. A los 2 años se detecta masa abdominal dependiente de hígado. Se diagnostica HB, por lo que requiere quimioterapia y cirugía (lobectomía izquierda). A 5 años de seguimiento está vivo sin actividad tumoral. Conclusiones. La asociación de SPR y HB no se encontró reportada previamente en la literatura. Ambas presentan alteraciones en el cromosoma 2. Dado que el cáncer cursa con alteraciones citogenéticas, debemos de establecer asociaciones entre aquellos pacientes que cursan con síndromes genéticos. Esto permite evaluar blancos moleculares útiles y diseñar terapias dirigidas. También permite detectar poblaciones de riesgo de padecer cáncer y crear programas de seguimiento y evaluación que permitan una detección temprana para mejorar la sobrevida de dichos grupos. Se trata del primer caso de asociación entre estas dos patologías reportado en nuestro instituto y en el mundo.
Background. Pierre-Robin Sequence (PRS) is a congenital disease characterized by micrognatia, glosoptosis and U-shaped posterior cleft palate. Its prevalence is 1:8500 newborns. Hepatoblastoma (HB) is the most frequent hepatic malignant tumor in childhood and affects patients <3 years of age. Case report. A 2-year old male with PRS was diagnosed with HB. The boy was the product of the second full term pregnancy. He was born by cesarean with a birth weight of 2750 g. The patient presented with a 1-month history of abdominal mass. Diagnosis of HB was done by biopsy. The patient received chemotherapy with cisplatin, vincristin and 5-fuorouracil as well as left lobectomy. Five years later he is alive without tumor activity. Conclusions. PRS and HB association has not been reported in the literature. Both entities have chromosome 2 alterations. Because cancer is associated with cytogenetic alterations, future considerations must be made to fnd a relationship between cancer patients and other genetic entities. This will be useful for fnding molecular targets. We can also detect the at-risk population in order to create follow-up programs that will allow an early diagnosis with an improved better survival. It is the frst case of PRS and HB reported in either the national or international literature.
RESUMEN
Background and purpose:Irinotecan plus fuorouracil/Leucovorin has become the standard regimen as the first-line in treating advanced colorectal cancer.We investigated the clinical response and side-effects of the first-line treatment with Irinotecan plus fuorouracil/ leucovorin(FOLFIRI) for advanced colorectal cancer.Methods:From may 2001 to march 2005,37 patients with advanced colorectal cancer were treat with irinotecan 180mg/m~(2) i.v.on day 2,and fuorouracil 400 mg/m~(2),bolus on day 1,2 and 1200 mg/m~(2),civ.44hour;leucovorin 200 mg/m~(2) i.v.on day 1,2,two weeks per cycle.Results:The response rate was 41.7%.Incidence of III/IV Grade myelosuppression was 35.1%/8.1%,and 4 patients suffered from febrile neutropenia.Incidence of III Grade delayed diarrhea was 8.1%.Conclusions:The first-line chemotherapy with a combination of irinotecan and fuorouracil/ leucovorin is effictive and well tolerated by patients with advanced colorectal cancer.